Build

CJC-1295 No DAC Guide: Growth Hormone Release Without the Bleed Effect

7 min read

CJC-1295 No DAC Guide: Growth Hormone Release Without the Bleed Effect

Why pulsatile GH release from Mod GRF 1-29 is preferred over continuous elevation — and how to build an effective GHRH protocol.

Source: https://indexalabs.com/blog/cjc-1295-no-dac-growth-hormone-guide Abstract: CJC-1295 No DAC (also known as Mod GRF 1-29) is a modified growth hormone-releasing hormone (GHRH) analogue that stimulates natural, pulsatile growth hormone release from the pituitary gland. Unlike its DAC (Drug Affinity Complex) counterpart which maintains elevated GH levels for days, the No DAC version produces sharp, physiological GH pulses that more closely mimic the body’s natural secretion pattern. This guide covers the science behind pulsatile vs. continuous GH release, optimal dosing protocols, and stacking strategies with GHRPs like Ipamorelin.

What Is CJC-1295 No DAC (Mod GRF 1-29)?

CJC-1295 No DAC is a synthetic analogue of growth hormone-releasing hormone (GHRH), the 44-amino-acid peptide produced by the hypothalamus that signals the anterior pituitary to release growth hormone. The “No DAC” designation distinguishes it from CJC-1295 with DAC (Drug Affinity Complex), a modified version that binds to albumin in the blood for extended half-life.

The original GHRH fragment (amino acids 1-29) called Sermorelin had a very short half-life of approximately 5–10 minutes, making it impractical for research protocols. Mod GRF 1-29 solves this by substituting four amino acids at positions 2, 8, 15, and 27 — modifications that resist enzymatic degradation while preserving full biological activity. The result is a half-life of approximately 30 minutes, long enough to produce a robust GH pulse but short enough to clear the system before the next dose.

Key distinction: “CJC-1295” alone is sometimes used loosely for both versions. Always verify whether a product is “No DAC” (Mod GRF 1-29, short-acting) or “with DAC” (long-acting, albumin-binding). They produce fundamentally different GH release patterns and are not interchangeable in research protocols.

Pulsatile vs. Continuous GH Release: Why It Matters

The human body releases growth hormone in distinct pulses — primarily during deep sleep, after exercise, and during fasting. These pulses are critical to how GH exerts its beneficial effects, and understanding this pattern explains why CJC-1295 No DAC is often preferred over the DAC version.

Natural GH Pattern: The pituitary releases GH in 6–12 pulses per day, with the largest occurring during Stage 3/4 deep sleep. Each pulse lasts approximately 1–2 hours, after which GH levels return to baseline. This pulsatile pattern is essential for:

  • Proper IGF-1 signalling in the liver
  • Maintaining GH receptor sensitivity
  • Preserving the hypothalamic feedback loop
  • Optimal fat metabolism and muscle protein synthesis

The “Bleed Effect” Problem: CJC-1295 with DAC maintains elevated GH levels for 6–10 days after a single injection. While this sounds convenient, continuous GH elevation causes:

  • GH receptor desensitisation (reduced response over time)
  • Disrupted feedback signalling (the pituitary “forgets” its natural rhythm)
  • Potential for more pronounced side effects (water retention, joint pain, insulin resistance)
  • Less efficient IGF-1 production per unit of GH released

Why No DAC Wins: CJC-1295 No DAC produces a sharp GH pulse lasting 2–3 hours, closely mimicking natural physiology. The pituitary recovers between doses, maintaining sensitivity and preserving the body’s endogenous GH production capacity. Research consistently shows that pulsatile GH administration produces better body composition outcomes per unit of GH released compared to continuous elevation.

CJC-1295 No DAC Dosing Protocol

Standard Protocol:

  • Dosage: 100 mcg per injection (1 mcg/kg is the research standard, but 100 mcg is the common fixed dose)
  • Frequency: 2–3 times daily
  • Timing: Upon waking (fasted), post-workout, and 30 minutes before bed
  • Administration: Subcutaneous injection, rotating sites (abdomen, upper arm, thigh)
  • Cycle length: 8–16 weeks, followed by 4–8 weeks off

Timing Considerations:

  • Morning dose (fasted): Amplifies the natural cortisol-driven GH pulse upon waking. Fasting is important — insulin blunts GH release. Wait 30–60 minutes after injection before eating.
  • Post-workout dose: Exercise is the most potent natural GH stimulator. Injecting CJC-1295 No DAC within 15 minutes after training amplifies this exercise-induced pulse significantly.
  • Pre-bed dose: The most important dose. It synchronises with the body’s largest natural GH pulse during deep sleep. Inject 30 minutes before sleep on an empty stomach (no food for 2+ hours prior).

Reconstitution:

  • Add 2 mL bacteriostatic water to a standard 2 mg vial
  • Each 0.1 mL (10 units on an insulin syringe) = 100 mcg
  • Refrigerate after reconstitution, use within 28 days
  • Swirl gently, never shake

What to Avoid:

  • Do not inject within 30 minutes of eating (insulin suppresses GH release)
  • Avoid high-fat meals for 2 hours after injection
  • Do not combine with exogenous insulin (dangerous and counterproductive)
  • Skip carb-heavy pre-bed meals when using the nighttime dose

Stacking CJC-1295 No DAC with GHRPs

CJC-1295 No DAC works through the GHRH receptor, but GH release is also regulated by a separate pathway — the ghrelin/GHS receptor. Growth hormone-releasing peptides (GHRPs) stimulate this second pathway. Using both together creates a synergistic effect that is substantially greater than either alone.

The Synergy Explained: GHRH (CJC-1295 No DAC) tells the pituitary to release GH. Ghrelin mimetics (GHRPs) reduce somatostatin — the hormone that inhibits GH release. Together, you get a larger GH pulse because you’re simultaneously pressing the accelerator and releasing the brake.

CJC-1295 No DAC + Ipamorelin (Most Popular Stack):

  • CJC-1295 No DAC: 100 mcg
  • Ipamorelin: 100–200 mcg
  • Combined in the same syringe, 2–3 times daily
  • Why: Ipamorelin is the most selective GHRP — it releases GH without significantly raising cortisol, prolactin, or ghrelin-driven hunger. Ideal for body recomposition without appetite disruption.

CJC-1295 No DAC + GHRP-6:

  • CJC-1295 No DAC: 100 mcg
  • GHRP-6: 100 mcg
  • Why: GHRP-6 produces stronger GH pulses than Ipamorelin and dramatically increases appetite. Useful for research protocols focused on muscle gain where increased caloric intake is desired.
  • Downside: Increases cortisol and prolactin more than Ipamorelin.

CJC-1295 No DAC + GHRP-2:

  • CJC-1295 No DAC: 100 mcg
  • GHRP-2: 100–200 mcg
  • Why: GHRP-2 produces the strongest GH release of the GHRPs but with moderate appetite increase and cortisol elevation. A middle ground between Ipamorelin’s selectivity and GHRP-6’s raw potency.

What to Expect: Timeline and Results

Weeks 1–2: Improved sleep quality is typically the first noticeable effect. Deeper sleep, more vivid dreams, and feeling more rested upon waking. This reflects enhanced GH pulsing during sleep stages.

Weeks 2–4: Improved skin quality (hydration, elasticity), faster recovery from exercise, and enhanced sense of well-being. Some researchers report improved nail growth and hair quality.

Weeks 4–8: Body composition changes become noticeable — gradual fat reduction (particularly visceral and abdominal fat), improved muscle tone, and better exercise performance. IGF-1 levels typically reach optimised ranges.

Weeks 8–16: Peak effects for body recomposition. Continued fat loss, improved lean mass retention during caloric restriction, enhanced joint and connective tissue health, and sustained energy levels.

What CJC-1295 No DAC Will NOT Do: It will not produce the dramatic, rapid changes associated with exogenous GH or anabolic steroids. It works by optimising your body’s own GH production — a gentler, more sustainable approach that preserves the pituitary’s function rather than suppressing it.

Blood Work Monitoring: Consider testing IGF-1 levels at baseline and at 4–6 weeks. A meaningful protocol should elevate IGF-1 by 30–80% from baseline. Fasting glucose should also be monitored, as elevated GH can reduce insulin sensitivity.

Safety Profile

CJC-1295 No DAC has a favourable safety profile, largely because it stimulates natural GH production rather than introducing exogenous growth hormone.

Common Effects (generally mild):

  • Flushing and warmth at injection site (resolves in 15–30 minutes)
  • Mild tingling or numbness in extremities (transient)
  • Increased water retention in the first 1–2 weeks (subsides)
  • Increased dream vividness and sleep depth

Potential Concerns at Higher Doses:

  • Joint pain or carpal tunnel-like symptoms (indicates excessive GH/IGF-1 — reduce dose)
  • Mild insulin resistance with prolonged use (monitor fasting glucose)
  • Headaches (uncommon, usually dose-related)

Contraindications:

  • Active cancer (GH can promote tumour growth)
  • Diabetes or significant insulin resistance (GH antagonises insulin)
  • Pregnancy and breastfeeding
  • Active intracranial pathology

Advantage over Exogenous GH: Because CJC-1295 No DAC works through the pituitary, the body’s natural feedback mechanisms remain intact. The pituitary will not produce more GH than its capacity allows, providing a built-in safety ceiling that exogenous GH injection does not have.

Graph View